"Skinny Labels" for Generic Drugs Under Hatch-Waxman Topic of White Paper From CRS
July 28, 2026
July 28, 2026
WASHINGTON, July 28 (TNSLrpt) -- The Congressional Research Service issued the following In Focus white paper (No. IF12700) by legislative attorney Kevin J. Hickey:
* * *
"Skinny Labels" for Generic Drugs Under Hatch-Waxman
New "brand-name" drugs are often protected from generic competition by patents. In general, a drug manufacturer intending to market a generic version of a brand-name drug must either wait for those patents to expire o . . .
* * *
"Skinny Labels" for Generic Drugs Under Hatch-Waxman
New "brand-name" drugs are often protected from generic competition by patents. In general, a drug manufacturer intending to market a generic version of a brand-name drug must either wait for those patents to expire o . . .